Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS

Upcoming catalysts could drive value creation at NASDAQ’s newest biotech, Boundless Bio, after it stumbled in its trading debut last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Boundless’ IPO in the context of the current market for fresh paper and profile the “sweat equity” model of Avalon, the VC firm led by Jay Lichter. Turning to Washington, BioCentury’s editors assess possible outcomes for the Supreme Court case on abortion drug mifepristone, and why the court’s pending decision could safeguard FDA from judicial second-guessing. The team also analyzes the agency’s first ever complete response letter for lack of confirmatory trial enrollment.  This week’s podcast is sponsored by Jeito Capital. View full story: https://www.biocentury.com/article/6519370:01 - Sponsor Message: Jeito Capital4:15 - Biotech IPOs7:50 - Avalon BioVentures11:14 - FDA at SCOTUS16:29 - Confirmatory TrialsReach us by sending a text